Suppressive effects of imidapril on th1- and th2-related chemokines in monocytes

Journal of Investigative Medicine

Volumn 59, Issue 7, 2011, Pages 1141-1146

  Tsai, Ming Kai ^a,b   Jan, Ren Long ^c   Lin, Ching Hsiung ^d,e   Kuo, Chang Hung ^f,g   Yang, San Nan ^f,g   Chen, Huan Nan ^g   Huang, Ming Yii ^f,h   Hung, Chih Hsing ^f,g,i  

^a KAOHSIUNG ARMED FORCES GENERAL HOSPITAL   (Taiwan)

^b MEIHO UNIVERSITY   (Taiwan)

^c CHI MEI MEDICAL CENTER   (Taiwan)

^d Department of Internal Medicine   (Taiwan)

^e CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^f Department of Otorhinolaryngology Head and Neck Surgery   (Taiwan)

^g KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^h KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

ⁱ Department of Pediatrics   (Taiwan)

Author keywords

I 309; Imidapril; IP 10; JNK; Monocyte; TNF

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMIDAPRIL; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; PERINDOPRIL; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ASSAY; GLOMERULONEPHRITIS; HUMAN; HUMAN CELL; IMMUNOMODULATION; MONOCYTE; TH1 CELL; TH2 CELL; WESTERN BLOTTING;

EID: 84863068195     PISSN: 17088267     EISSN: 17088267     Source Type: Journal    
DOI: 10.2310/JIM.0b013e31822ba7fb     Document Type: Article

References (25)

1. Shimohata H, Yamada A, Yoh K, et al. Overexpression of T-bet in T cells accelerates autoimmune glomerulonephritis in mice with a dominant Th1 background. J Nephrol. 2009;22:123-129.
2. Cheng Y, Zhang J, Hou W, et al. Immunoregulatory effects of sinomenine on the T-bet/GATA-3 ratio and Th1/Th2 cytokine balance in the treatment of mesangial proliferative nephritis. Int Immunopharmacol. 2009;9:894-899.
3. Morimoto S, Tokano Y, Nakano S, et al. Chemoattractant mechanism of Th1 cells in class III and IV lupus nephritis. Autoimmunity. 2009;42:143-149.
4. Stoian M, Radulian G, Chicac D, et al. A clinical approach in regression of glomerulosclerosis. Rom J Intern Med. 2007;45:215-218.
5. Tao JL, Li H, Tang Y, et al. Lupus nephritis complicated with malignant hypertension: from renal vascular pathology to clinical relevance. Chin Med Sci J. 2008;23:81-87. (Pubitemid 352000969)
6. Pazik J, Ostrowska J, Lewandowski Z, et al. Renin-angiotensin-aldosterone system inhibitors and statins prolong graft survival in post-transplant glomerulonephritis. Ann Transplant. 2008;13:41-45.
7. Rönnblom L, Elkon KB. Cytokines as therapeutic targets in SLE. Nat Rev Rheumatol. 2010;6:339-347.
8. Martinez FO, Gordon S, Locati M, et al. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol. 2006;177:7303-7311. (Pubitemid 44715100)
9. Mantovani A, Sica A, Sozzani S, et al. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004;25:677-686. (Pubitemid 39457982)
10. Luster AD. Chemokines: chemotactic cytokines that mediate inflammation. N Engl J Med. 1998;338:436-445. (Pubitemid 28135672)
11. Fu Q, Chen X, Cui H, et al. Association of elevated transcript levels of interferon-inducible chemokines with disease activity and organ damage in systemic lupus erythematosus patients. Arthritis Res Ther. 2008;10:R112.
12. Panzer U, Steinmetz OM, Paust HJ, et al. Chemokine receptor CXCR3 mediates T cell recruitment and tissue injury in nephrotoxic nephritis in mice. J Am Soc Nephrol. 2007;18:2071-2084. (Pubitemid 47041073)
13. Segerer S, Banas B, Wö rnle M, et al. CXCR3 is involved in tubulointerstitial injury in human glomerulonephritis. Am J Pathol. 2004;164:635-649. (Pubitemid 38364678)
14. Okamoto H, Koizumi K, Yamanaka H, et al. A role for TARC/CCL17, a CC chemokine, in systemic lupus erythematosus. J Rheumatol. 2003;30:2369-2373. (Pubitemid 37413895)
15. Suganuma T, Mushegian A, Swanson SK, et al. The ATAC acetyltransferase complex coordinates MAP kinases to regulate JNK target genes. Cell. 2010;142:726-736.
16. Uhm WS, Lee HS, Chung YH, et al. Angiotensin-converting enzyme gene polymorphism and vascular manifestations in Korean patients with SLE. Lupus. 2002;11:227-233.
17. De Albuquerque DA, Saxena V, Adams DE, et al. An ACE inhibitor reduces Th2 cytokines and TGF-A1 and TGF-A2 isoforms in murine lupus nephritis. Kidney Int. 2004;65:846-859. (Pubitemid 38251060)
18. Ide N, Hirase T, Nishimoto-Hazuku A, et al. Angiotensin II increases expression of IP-10 and the renin-angiotensin system in endothelial cells. Hypertens Res. 2008;31:1257-1267.
19. Hung CH, Suen JL, Hua YM, et al. Suppressive effects of ketotifen on Th1- and Th2-related chemokines of monocytes. Pediatr Allergy Immunol. 2007;18:378-384.
20. Weiss T, Shalit I, Blau H, et al. Anti-inflammatory effects of moxifloxacin on activated human monocytic cells: inhibition of NF-JB and mitogen-activated protein kinase activation and of synthesis of proinflammatory cytokines. Antimicrob Agents Chemother. 2004;48:1974-1982. (Pubitemid 38691585)
21. Bhattacharyya A, Pathak S, Datta S, et al. Mitogen-activated protein kinases and nuclear factor-JB regulate Helicobacter pylori-mediated interleukin-8 release from macrophages. Biochem J. 2002;368: 121-129. (Pubitemid 35463415)
22. Brugts JJ, Ferrari R, Simoons ML. Angiotensin-converting enzyme inhibition by perindopril in the treatment of cardiovascular disease. Expert Rev Cardiovasc Ther. 2009;7:345-360.
23. Vandenburg MJ, Mackay EM, Dews I, et al. Dose finding studies with imidaprilVa new ACE inhibitor. Br J Clin Pharmacol. 1994;37:265-272. (Pubitemid 24212187)
24. Robinson DM, Curran MP, Lyseng-Williamson KA. Imidapril: a review of its use in essential hypertension, type 1 diabetic nephropathy and chronic heart failure. Drugs. 2007;67:1359-1378. (Pubitemid 46887272)
25. Dandona P, Kumar V, Aljada A, et al. Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-JB, in mononuclear cells of normal subjects: evidence of an antiinflammatory action. J Clin Endocrinol Metab. 2003;88:4496-4501. (Pubitemid 37153762)